{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:02:39Z","timestamp":1793289759471,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40259-023-00625-2","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T13:01:55Z","timestamp":1695387715000},"page":"145-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct0428522","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yu","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cibo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9762-2663","authenticated-orcid":false,"given":"Hejian","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"12","key":"625_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis. 2021;80(12):1511\u201321. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221035.","journal-title":"Ann Rheum Dis"},{"issue":"10089","key":"625_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4.","journal-title":"Lancet"},{"issue":"6","key":"625_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3111\/13696998.2012.692341","volume":"15","author":"X Gao","year":"2012","unstructured":"Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054\u201363. https:\/\/doi.org\/10.3111\/13696998.2012.692341.","journal-title":"J Med Econ"},{"issue":"9","key":"625_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). 2016;68(9):1320\u201331. https:\/\/doi.org\/10.1002\/acr.22831.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"625_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11926-022-01079-1","volume":"24","author":"S Zhang","year":"2022","unstructured":"Zhang S, Peng L, Li Q, Zhao J, Xu D, Zhao J, et al. Spectrum of spondyloarthritis among Chinese populations. Curr Rheumatol Rep. 2022;24(8):247\u201358. https:\/\/doi.org\/10.1007\/s11926-022-01079-1.","journal-title":"Curr Rheumatol Rep"},{"key":"625_CR6","first-page":"4","volume":"78","author":"A Boonen","year":"2006","unstructured":"Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl. 2006;78:4\u201311.","journal-title":"J Rheumatol Suppl"},{"issue":"5","key":"625_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/1756-185x.14102","volume":"24","author":"OV Yurdakul","year":"2021","unstructured":"Yurdakul OV, Ince OE, Bagcier F, Kara M, Kultur E, Aydin T. Evaluating the strength of spinal and proximal girdle muscles in patients with axial spondyloarthritis: correlation with activity, disability, and functionality. Int J Rheum Dis. 2021;24(5):701\u201310. https:\/\/doi.org\/10.1111\/1756-185x.14102.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"625_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/1756-185x.13510","volume":"22","author":"LS Tam","year":"2019","unstructured":"Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, et al. 2018 APLAR axial spondyloarthritis treatment recommendations. Int J Rheum Dis. 2019;22(3):340\u201356. https:\/\/doi.org\/10.1111\/1756-185x.13510.","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"625_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599\u2013613. https:\/\/doi.org\/10.1002\/art.41042.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"625_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"625_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/rheumatology\/keaa435","volume":"59","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Siebert S. Treatment strategies in axial spondyloarthritis: what, when and how? Rheumatol (Oxf). 2020;59(Suppl 4):79\u201389. https:\/\/doi.org\/10.1093\/rheumatology\/keaa435.","journal-title":"Rheumatol (Oxf)"},{"issue":"1","key":"625_CR12","doi-asserted-by":"publisher","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","volume":"3","author":"A Sepriano","year":"2017","unstructured":"Sepriano A, Regel A, van der Heijde D, Braun J, Baraliakos X, Landew\u00e9 R, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396. https:\/\/doi.org\/10.1136\/rmdopen-2016-000396.","journal-title":"RMD Open"},{"issue":"5","key":"625_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14740338.2018.1448785","volume":"17","author":"S D'Angelo","year":"2018","unstructured":"D\u2019Angelo S, Carriero A, Gilio M, Ursini F, Leccese P, Palazzi C. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17(5):475\u201386. https:\/\/doi.org\/10.1080\/14740338.2018.1448785.","journal-title":"Expert Opin Drug Saf"},{"key":"625_CR14","unstructured":"Eli Lilly and Company: Taltz 80 mg (ixekizumab) solution for injection in pre-filled syringe. Summary of medical product characteristics. 2022. https:\/\/www.ema.europa.eu\/documents\/product-information\/taltz-epar-product-information_en.pdf. Accessed Dec 2022."},{"key":"625_CR15","unstructured":"Eli Lilly and Company: TALTZ (ixekizumab) injection, for subcutaneous use. Prescribing information. 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125521s004lbl.pdf. Accessed Dec 2022."},{"issue":"2","key":"625_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, Sieper J, Baraliakos X, Van den Bosch F, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis. 2020;79(2):176\u201385. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216118.","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"625_CR17","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/s0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying antirheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351. https:\/\/doi.org\/10.1016\/s0140-6736(18)31946-9.","journal-title":"Lancet"},{"issue":"4","key":"625_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthritis Rheumatol. 2019;71(4):599\u2013611. https:\/\/doi.org\/10.1002\/art.40753.","journal-title":"Arthritis Rheumatol"},{"issue":"9993","key":"625_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60125-8.","journal-title":"Lancet"},{"issue":"10086","key":"625_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389(10086):2317\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(17)31429-0.","journal-title":"Lancet"},{"issue":"1","key":"625_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209709.","journal-title":"Ann Rheum Dis"},{"key":"625_CR22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221022","author":"A Deodhar","year":"2023","unstructured":"Deodhar A, Poddubnyy D, Rahman P, Ermann J, Tomita T, Bolce R, et al. Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program. J Rheumatol. 2023. https:\/\/doi.org\/10.3899\/jrheum.221022.","journal-title":"J Rheumatol"},{"key":"625_CR23","unstructured":"Ixekizumab_Chinese_PI. Ixekizumab Chinese prescribing information. 2023. https:\/\/www.lillymedical.cn\/books\/%E4%BE%9D%E5%A5%87%E7%8F%A0%E5%8D%95%E6%8A%97%E6%B3%A8%E5%B0%84%E6%B6%B2%E8%AF%B4%E6%98%8E%E4%B9%A6.pdf. Accessed Jan 2023."},{"issue":"4","key":"625_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361\u20138. https:\/\/doi.org\/10.1002\/art.1780270401.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"625_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):1\u201344. https:\/\/doi.org\/10.1136\/ard.2008.104018.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"625_CR26","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286\u201391.","journal-title":"J Rheumatol"},{"issue":"8","key":"625_CR27","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::Aid-art326>3.0.Co;2-f","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44(8):1876\u201386. https:\/\/doi.org\/10.1002\/1529-0131(200108)44:8%3c1876::Aid-art326%3e3.0.Co;2-f.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"625_CR28","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/ard.2003.016717","volume":"63","author":"J Brandt","year":"2004","unstructured":"Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis. 2004;63(11):1438\u201344. https:\/\/doi.org\/10.1136\/ard.2003.016717.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"625_CR29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","volume":"77","author":"PM Machado","year":"2018","unstructured":"Machado PM, Landew\u00e9 R, Heijde DV. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states. Ann Rheum Dis. 2018;77(10):1539\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213184.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"625_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/rheumatology\/34.8.793","volume":"34","author":"A Calin","year":"1995","unstructured":"Calin A, Jones SD, Garrett SL, Kennedy LG. Bath ankylosing spondylitis functional index. Br J Rheumatol. 1995;34(8):793\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/34.8.793.","journal-title":"Br J Rheumatol"},{"issue":"4","key":"625_CR31","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/art.21337","volume":"53","author":"WP Maksymowych","year":"2005","unstructured":"Maksymowych WP, Inman RD, Salonen D, Dhillon SS, Krishnananthan R, Stone M, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum. 2005;53(4):502\u20139. https:\/\/doi.org\/10.1002\/art.21337.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"625_CR32","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S47-58. https:\/\/doi.org\/10.1002\/acr.20575.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"625_CR33","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230\u20136. https:\/\/doi.org\/10.1002\/art.11325.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"625_CR34","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389. https:\/\/doi.org\/10.1002\/art.21306.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"625_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3899\/jrheum.091042","volume":"37","author":"RD Inman","year":"2010","unstructured":"Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37(6):1203\u201310. https:\/\/doi.org\/10.3899\/jrheum.091042.","journal-title":"J Rheumatol"},{"issue":"7","key":"625_CR36","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136\u201346. https:\/\/doi.org\/10.1002\/art.21913.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"625_CR37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204231.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"625_CR38","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis. 2017;76(3):571\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210023.","journal-title":"Ann Rheum Dis"},{"issue":"9906","key":"625_CR39","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/s0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705\u201313. https:\/\/doi.org\/10.1016\/s0140-6736(13)61134-4.","journal-title":"Lancet"},{"issue":"8","key":"625_CR40","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/1744666x.2020.1803063","volume":"16","author":"JX Huang","year":"2020","unstructured":"Huang JX, Lee YH, Wei JC. Ixekizumab for the treatment of ankylosing spondylitis. Expert Rev Clin Immunol. 2020;16(8):745\u201350. https:\/\/doi.org\/10.1080\/1744666x.2020.1803063.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"625_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3899\/jrheum.170429","volume":"45","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Gladman DD, Kishimoto M, Okada M, Rathmann SS, Moriarty SR, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1). J Rheumatol. 2018;45(3):367\u201377. https:\/\/doi.org\/10.3899\/jrheum.170429.","journal-title":"J Rheumatol"},{"issue":"4","key":"625_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/jd9.0000000000000244","volume":"5","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan W-L, Zheng M, Lu Y, Li F-Q, et al. Efficacy and safety of ixekizumab in chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase 3 study. Int J Dermatol Venereol. 2022;5(4):181\u201390. https:\/\/doi.org\/10.1097\/jd9.0000000000000244.","journal-title":"Int J Dermatol Venereol"},{"issue":"6","key":"625_CR43","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","volume":"39","author":"S Chabra","year":"2022","unstructured":"Chabra S, Gill BJ, Gallo G, Zhu D, Pitou C, Payne CD, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther. 2022;39(6):2862\u201372. https:\/\/doi.org\/10.1007\/s12325-022-02126-0.","journal-title":"Adv Ther"},{"issue":"52","key":"625_CR44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.46234\/ccdcw2020.266","volume":"2","author":"S Yu","year":"2020","unstructured":"Yu S, Ma J, Jia Z. Estimating the incidence of tuberculosis\u2014Shanghai, China, 2025\u20132050. China CDC Wkly. 2020;2(52):995\u20138. https:\/\/doi.org\/10.46234\/ccdcw2020.266.","journal-title":"China CDC Wkly"},{"issue":"12","key":"625_CR45","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatol (Oxf). 2020;59(12):3834\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/keaa189.","journal-title":"Rheumatol (Oxf)"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00625-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00625-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T14:23:52Z","timestamp":1705415032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00625-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00625-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"assertion":[{"value":"11 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sponsorship for this study was provided by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dongzhou Liu and Cibo Huang received research grants from Eli Lilly and Company. Yan Yan and Rong Chen are employees and shareholders of Eli Lilly and Company. Fei Ji was an employee and shareholder of Eli Lilly and Company during the period of this work. Yu Xue, Jiankang Hu, Jingyang Li, Huaxiang Wu, Chunyu Tan, Lie Dai, Lingyun Sun, Zhijun Li, Zhengyu Xiao, and Hejian Zou have no conflicts of interest to declare in relation to this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study protocol was approved by local ethics committees and the study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences International Ethical Guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients gave written, informed consent before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available upon reasonable request. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data-sharing environment. For details on submitting a request, see the instructions provided at .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors of this article meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility for the integrity of the work as a whole, and have provided approval for this version to be published. All authors contributed to the study conception and design. Hejian Zou, Yu Xue, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Chunyu Tan, Lie Dai, Lingyun Sun, Zhijun Li, Zhengyu Xiao and Cibo Huang contributed to the acquisition of data. Fei Ji contributed to data analysis. Substantial contributions to the interpretation of data were provided by all authors. The first draft of the manuscript was written by Jake Burrell, PhD, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Partial results presented in this manuscript were presented as posters at the American College of Rheumatology (ACR) Congress 2022 (10\u201314 November 2022) and the Asia-Pacific League of Associations for Rheumatology (APLAR) congress 2022 (6\u20139 December 2022).","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior presentation"}}]}}